Alkermes (ALKS) Net Income towards Common Stockholders (2010 - 2026)

Alkermes' (ALKS) quarterly Net Income towards Common Stockholders came in at -$66.5 million in Q1 2026, down 168.87% on a QoQ basis from $96.6 million in Q4 2025.

Alkermes (ALKS) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends

Alkermes (ALKS) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$66.5 million in Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders changed N/A year-over-year to -$66.5 million in Q1 2026; TTM through Mar 2026 was $30.1 million, a 904.79% increase from a year earlier, with the FY2025 full-year figure at $288.9 million, up 5090.05% from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 stood at -$66.5 million, down from $96.6 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for ALKS reached as high as $96.6 million in Q4 2025 and fell as low as -$66.5 million in Q1 2026.
  • Historically, Net Income towards Common Stockholders has averaged -$13.1 million across 5 years, with a median of -$33.0 million in 2022.
  • Across the five-year window, Net Income towards Common Stockholders tumbled 1374.79% in 2022 and soared 219447.73% in 2025, its largest moves.
  • Year by year, Net Income towards Common Stockholders stood at $87.7 million in 2022, then sank by 146.58% to -$40.9 million in 2023, then jumped by 100.11% to $44000.0 in 2024, then surged by 219447.73% to $96.6 million in 2025, then slumped by 168.87% to -$66.5 million in 2026.
  • Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$66.5 million in Q1 2026, $96.6 million in Q4 2025, and $44000.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 88.07 Bn 86.20 Bn - -
2 Teva Pharmaceutical Industries 35.75 Bn 32.01 Bn 1.97 Bn 370.00 Mn
3 Zoetis 31.84 Bn 29.90 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 27.18 Bn 23.12 Bn 4.39 Bn -2.35 Bn
5 United Therapeutics 23.09 Bn 20.93 Bn 648.10 Mn 274.90 Mn
6 RedHill Biopharma 21.32 Bn 21.32 Bn - -
7 Viatris 19.96 Bn 18.16 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.66 Bn 16.34 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.44 Bn 12.02 Bn 785.00 Mn 57.00 Mn
10 Alkermes 8.78 Bn 8.27 Bn 331.33 Mn -66.53 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -66.53 Mn
Dec 31, 2025 96.60 Mn
Dec 31, 2024 44,000.00
Sep 30, 2024 -481,000.00
Jun 30, 2024 -3.30 Mn
Mar 31, 2024 -2.12 Mn
Dec 31, 2023 -40.86 Mn
Sep 30, 2023 -45.35 Mn
Jun 30, 2023 -42.04 Mn
Mar 31, 2023 -36.52 Mn
Dec 31, 2022 87.72 Mn
Sep 30, 2022 -63.97 Mn
Jun 30, 2022 -30.14 Mn
Mar 31, 2022 -35.90 Mn
Dec 31, 2021 137.03 Mn
Sep 30, 2021 -28.99 Mn
Jun 30, 2021 2.36 Mn
Mar 31, 2021 -22.42 Mn
Dec 31, 2020 -29.62 Mn
Sep 30, 2020 -134,000.00